| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IGHG3 |
| Uniprot No | P01860 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-521aa |
| 氨基酸序列 | MEFGLSWVLLVVFLQGVQCEVQLVDSGGGLVQPGGSLRLSCAASGFIVSDHYVEWVRQAPGKGPEWVGCFRSKAHKSTTEYAASVKGRFTILRDDSKNSVHLQMNSLKTDDTAVYYCVRDLEGAGKYDWYFDIWGRGILVTVSSASTKGPSVFPLAPCSRSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYTCNVNHKPSNTKVDKRVELKTPLGDTTHTCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFKWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESSGQPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQGNIFSCSVMHEALHNRFTQKSLSLSPGK |
| 分子量 | 83.6 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人IGHG3蛋白的模拟参考文献示例，基于典型研究方向和文献结构整理而成：
---
1. **"Structural Insights into Recombinant Human IgG3 and Its Enhanced Complement Activation"**
*作者：Smith J, et al. (2020)*
**摘要**：本研究利用哺乳动物表达系统成功重组表达人IgG3抗体，并通过晶体学分析其长铰链区结构。结果表明，重组IgG3的独特铰链结构显著增强C1q结合能力，解释了其高效的补体激活特性，为设计基于IgG3的治疗抗体提供依据。
2. **"Comparative Functional Analysis of Recombinant IgG Subtypes in Viral Neutralization"**
*作者：Zhang L, et al. (2018)*
**摘要**：文章比较了重组人IgG1、IgG3与其他亚型的中和活性，发现IgG3因延长的铰链区在空间上更易结合多价抗原，在体外模型中表现出对包膜病毒更强的中和能力，但其半衰期较短可能限制临床应用。
3. **"Optimizing Recombinant IgG3 Production in CHO Cells: Impact of Glycosylation and Yield"**
*作者：Kim H, et al. (2019)*
**摘要**：研究通过优化CHO细胞培养条件和糖基化工程，提高了重组IgG3的产量并调控其糖型。结果显示特定糖型修饰可平衡IgG3的效应功能与稳定性，为规模化生产提供技术方案。
4. **"IgG3 Autoantibodies in Autoimmune Diseases: Roles and Therapeutic Potential"**
*作者：Brown K, et al. (2021)*
**摘要**：该综述探讨了重组IgG3在自身免疫疾病中的双重角色：既可能通过强效的效应功能加重病理，也可通过工程化改造(如Fc沉默突变)转化为抗炎载体，强调了其在靶向治疗中的潜力。
---
**备注**：以上文献为示例性质，实际研究中建议通过PubMed或Google Scholar以关键词“recombinant human IgG3”“IgG3 Fc function”等检索最新文献。真实文献可能更多聚焦于IgG3的结构生物学、疾病关联或生产优化等领域。
Recombinant human IGHG3 protein refers to a genetically engineered form of the heavy chain constant region (Fc region) of immunoglobulin gamma 3 (IgG3), one of the four subclasses of human IgG antibodies. IgG3 plays distinct roles in immune responses due to its extended hinge region, which enhances flexibility and effector functions like complement activation and Fc receptor binding. This subclass is associated with prolonged inflammatory responses and exhibits superior potency in combating pathogens compared to other IgG subtypes.
Produced via recombinant DNA technology, IGHG3 is typically expressed in mammalian cell systems (e.g., CHO or HEK293) to ensure proper post-translational modifications, such as glycosylation, critical for functional integrity. Researchers employ recombinant IGHG3 to study antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and Fc-mediated immune regulation. It also serves as a tool in therapeutic antibody engineering, enabling optimization of antibody therapies for diseases like cancer or autoimmune disorders by tuning Fc effector functions. Additionally, it aids in developing diagnostic assays and standardized controls for immunogenicity studies. The recombinant format ensures batch-to-batch consistency, scalability, and reduced ethical concerns compared to animal-derived antibodies. Its applications span immunology, biopharmaceutical development, and molecular diagnostics, underscoring its importance in understanding humoral immunity and advancing biologics.
×
